Palleiko Benjamin L's Form 4 filing
KalVista Pharmaceuticals, Inc. (KALV) · filed Jul 10, 2025
- Accession no.
- 0001415889-25-019657
- Filed
- Jul 10, 2025
- Trade date
- Jul 8-9, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $517.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Palleiko Benjamin LCIK 0001366244 | Director, Officer (CHIEF EXECUTIVE OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 8, 2025 | Common Stock | AGrant or awardAcquired | +87,500 | –F2 | – | 402,574 | Direct | |
| Jul 9, 2025 | Common Stock | SSaleDisposed | −32,979 | $15.69 | −$517,440.51 | 369,595 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Each PSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Referenced by the price of 1 transaction in Table I.